Leerink Partnrs Weighs in on Fusion Pharmaceuticals Inc.'s Q1 2024 Earnings (NASDAQ:FUSN)

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) - Research analysts at Leerink Partnrs reduced their Q1 2024 earnings per share (EPS) estimates for Fusion Pharmaceuticals in a report released on Tuesday, April 9th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings per share of ($0.37) for the quarter, down from their prior estimate of ($0.33). Leerink Partnrs currently has a "Market Perform" rating on the stock. The consensus estimate for Fusion Pharmaceuticals' current full-year earnings is ($1.45) per share. Leerink Partnrs also issued estimates for Fusion Pharmaceuticals' Q2 2024 earnings at ($0.39) EPS, Q3 2024 earnings at ($0.41) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.59) EPS and FY2025 earnings at ($1.62) EPS.

Fusion Pharmaceuticals (NASDAQ:FUSN - Get Free Report) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 46.59%.

A number of other equities research analysts also recently weighed in on the stock. Oppenheimer raised their target price on shares of Fusion Pharmaceuticals from $13.00 to $15.00 and gave the company an "outperform" rating in a research note on Friday, January 5th. William Blair downgraded shares of Fusion Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Tuesday, March 19th. Truist Financial reaffirmed a "hold" rating and issued a $21.00 target price (up from $11.00) on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. SVB Leerink reaffirmed a "market perform" rating and issued a $21.00 target price (up from $17.00) on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. Finally, Wedbush downgraded shares of Fusion Pharmaceuticals from an "outperform" rating to a "neutral" rating and set a $24.00 price target on the stock. in a research note on Tuesday, March 19th. Twelve analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, Fusion Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $20.25.

Fusion Pharmaceuticals Price Performance

FUSN traded down $0.05 on Friday, reaching $21.31. The company had a trading volume of 527,894 shares, compared to its average volume of 2,144,228. The business has a 50 day simple moving average of $15.07 and a 200 day simple moving average of $9.19. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -14.50 and a beta of -0.72. The company has a debt-to-equity ratio of 0.16, a quick ratio of 15.01 and a current ratio of 15.01. Fusion Pharmaceuticals has a 52-week low of $2.31 and a 52-week high of $21.55.

Institutional Investors Weigh In On Fusion Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in FUSN. Yarbrough Capital LLC purchased a new stake in shares of Fusion Pharmaceuticals in the 4th quarter worth about $739,000. Forefront Analytics LLC lifted its position in shares of Fusion Pharmaceuticals by 67.8% in the 3rd quarter. Forefront Analytics LLC now owns 33,685 shares of the company's stock worth $88,000 after purchasing an additional 13,610 shares during the period. Avidity Partners Management LP lifted its position in shares of Fusion Pharmaceuticals by 1.4% in the 3rd quarter. Avidity Partners Management LP now owns 5,781,850 shares of the company's stock worth $15,033,000 after purchasing an additional 81,850 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Fusion Pharmaceuticals in the 4th quarter worth about $80,000. Finally, Federated Hermes Inc. lifted its position in shares of Fusion Pharmaceuticals by 0.5% in the 3rd quarter. Federated Hermes Inc. now owns 10,683,789 shares of the company's stock worth $27,778,000 after purchasing an additional 50,000 shares during the period. Hedge funds and other institutional investors own 72.85% of the company's stock.

About Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.